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Curcumin enhances the cytotoxic and chemosensitising effects of lenalidomide
in human multiple myeloma cells
Abstract
Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate
the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma
cell lines and a nude mice model. Its effect on the other IMid, lenalidomide, has not been evaluated. This
study aims to investigate the mechanism of action of curcumin and its potential ability to positively
interact with lenalidomide. Method: we designed an in-vitro study to investigate the cytotoxic and chemosensitising effects of curcumin alone and in combination with lenalidomide on the human myeloma H929
cell line. Results: Incubation of H929 cells with curcumin (30mM) or lenalidomide (2.5 mM) for 3 days
resulted in 26.35% (±1.06) and 30.81%(±2.98) apoptotic cells respectively. When 30 mM curcumin was
combined with 2.5 mM lenalidomide, 50.4% (±3.37) apoptotic cells were detected by flow cytometry and
the increase was significant compared to either curcumin alone or lenalidomide alone (anova p = 0.0026).
Furthermore, gene analysis studies show that curcumin enhances the cytotoxic effect of lenalidomide via
suppression of the cereblon and multi-drug resistant genes. Conclusion: Curcumin exerts a cytotoxic
effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemosensitizing effects of this agent.
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Abstract
Background: Curcumin, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the
immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model.
Its effect on the other IMid, lenalidomide, has not been evaluated. This study aims to investigate the mechanism of action
of curcumin and its potential ability to positively interact with lenalidomide.
Method: we designed an in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in
combination with lenalidomide on the human myeloma H929 cell line.
Results: Incubation of H929 cells with curcumin (30M) or lenalidomide (2.5 mM) for 3 days resulted in 26.35% (±1.06)
and 30.81%(±2.98) apoptotic cells respectively. When 30 M curcumin was combined with 2.5 mM lenalidomide, 50.4%
(±3.37) apoptotic cells were detected by flow cytometry and the increase was significant compared to either curcumin
alone or lenalidomide alone (anova p = 0.0026). Furthermore, gene analysis studies show that curcumin enhances the
cytotoxic effect of lenalidomide via suppression of the cereblon and multi-drug resistant genes.
Conclusion: Curcumin exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also
enhances the chemo-sensitizing effects of this agent.
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1 Introduction
Current treatment options for patients with multiple myeloma include the use of a combination of cytotoxic drugs and
immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, bortezomib and pomalidomide [1, 2]. IMiDs have
been shown to have anti-inflammatory, anti-angiogenic, pro-apoptotic and immunomodulatory properties [3, 4]. Despite
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their therapeutic potential, only 80% of patients with myeloma respond to IMiDs-based therapy
determine response to IMiDs have not been clearly defined.

[1]

. Factors which

Curcumin, the active component of the Curcuma longa plant, displays a wide range of biological activities including
anti-oxidant, anti-inflammatory and cytotoxicity to numerous cancer cell types [5]. Its anti-cancer effect has been attributed
to regulation of multiple cell signalling pathways involved in cell proliferation and apoptosis [6]. In vitro and in vivo studies
have shown that curcumin inhibits activation of nuclear factor-kappa B (NF-kappa B), a transcription factor closely linked
to chemoresistance , in various types of haematological as well as non-haematological cancers [7-9]. Sung et al [10] have
shown that curcumin can circumvent chemoresistance in vitro and potentiate the effect of thalidomide and bortezomib
against human multiple myeloma in a nude mouse model. Bai & Zhang [11] have shown that curcumin enhances the
cytotoxic effects of bortezomib in a human multiple myeloma cell line.
Recent clinical studies have demonstrated that oral administration of curcumin, even at high doses, is well tolerated and
can decrease the paraprotein load, free light chains, bone turnover and % plasma cell infiltrate into the bone marrow in
some patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma
(SMM) [12-15].
Given that both curcumin and IMiDs have demonstrated pro-apoptotic and chemo-sensitising properties, we designed an
in-vitro study to investigate the cytotoxic and chemo-sensitising effects of curcumin alone and in combination with
lenalidomide on the human myeloma cell line H929.

2 Materials and methods
2.1 Cell culture
The human myeloma cell line H929 was obtained from the ATCC and maintained in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), penicillin (100U/ml) and streptomycin (100ug/ml) at 37oC in an atmosphere of 5%
CO2.
Curcumin (C3 complex from Sabinsa Corporation, Piscataway, NJ, containing 3 curcuminoids ie curcumin, desmethoxycurcumin and bisdesmethoxycurcumin) was dissolved in DMSO at 1mM as a stock solution and stored at -20oC.
Lenalidomide was dissolved in DMSO (Dimethylsulfoxide) at 200 mM as a stock solution and stored at -20oC. For in vitro
use, dilutions of the stock solutions were made in culture medium, and filter sterilised. The maximum concentration of
DMSO in the culture medium (1%) had no effect on cell death of H929 cells.

2.2 Evaluation of apoptosis
Cells treated with curcumin and/or lenalidomide were cultured for 3 days before they were analysed for apoptosis using
the Annexin V-FITC kit (Miltenyi Biotech). One million cells were washed and resuspended in binding buffer and stained
with 10µl of Annexin V-FITC for 15 minutes at room temperature in the dark. The cells were washed once with 1 ml of
binding buffer and resuspended in 500µl of binding buffer. Five microliter of propidium iodide (PI) solution (provided)
was added immediately prior to analysis by flow cytometry.

2.3 Sample preparation and real-time PCR
All cells used for real-time PCR analysis were cultured under the same conditions as those for evaluation of apoptosis,
however the culture period was 2 instead of 3 days. Total RNA was extracted from the cells using the RNeasy mini kit
(Qiagen, Melbourne, Australia), followed by complimentary DNA (cDNA) synthesis using the Superscript III first strand
synthesis kit (Invitrogen, Melbourne, Australia). Real time PCR was performed on the lenalidomide target gene cereblon
2
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using 5’-C
CTCCTGCCTG
GCAGAGAGT
TGAGG-3’ and
a
5’-TGCTC
CATCGTGCA
AAAGTCCTGC- 3’ primerrs (NCBI
Nucleotidee reference NM
M_016302.3 ); the
t multi-drug resistant genee (MDR) usingg 5’-AAGCAG
GAGGCCGCTG
GTTCGT3’ and 5’-A
ATCCATCCCG
GACCTCGCG
GCT-3’ (NCBI Nucleotide re ference NM_ 0000927.4); andd the multi-druug resistant
protein (M
MRP) using 5’-TGGGCATC
5
CACCATGCT
TGCTT -3’ aand 5’-ACAG
GGTCCACCTG
GGGCATCC-33’ (NCBI
Nucleotidee reference NM
M_004996.3 ). All
A real time PC
CR was run onn a Rotor Gene RG-3000 instrrument (Corbettt, Qiagen,
Australia), using the KAP
PA SYBR fast real-time
r
PCR kit (Geneworkks, Adelaide, A
Australia). Dataa were analysedd using the
comparativ
ve cycle thresh
hold (CT) meethod normalissed to the enddogenous referrence gene 188S (Qiagen, M
Melbourne,
Australia), and relative to
o a calibrator (n
normalised ct value
v
obtained from untreatedd cells), whichh was expressedd as 2-DDct.
The fold ch
hange in the ex
xpression of thee mRNA due to
o treatment waas calculated ass -1/2-DDct [16].

3 Results
3.1 Apoptotic effects
e
of curcumin and len
nalidomid
de alone and in
nation on
n H929 ce
ells
combin
The effect of
o curcumin an
nd lenalidomid
de (LEN), either alone or in coombination, onn apoptosis of H
H929 cells wass measured
as the % of annexin V positive cells by
y flow cytomeetry after a 3-dday incubation period. Incubaation of H929 cells with
curcumin or
o LEN resulted in a dose-dependent increaase in cell deatth. Curcumin ddemonstrated a cytotoxic effeect against
H929 cells with an IC50 at 40 µM (seee Figure 1A) and
a was used aat 30 M for ssubsequent expperiments. Thee apoptotic
effect of LE
EN reached a plateau
p
at 3 mM
M resulting in approximately
a
770% cell deathh after 3 days (ssee Figure 1B).. LEN was
used at 2.5 mM for subseequent experim
ments.

Figure 1 A

Figure 1 B

ubation at varioous concentratiions of curcum
min (A) and LE
EN (B).
Figure 1. Apoptotic H929 cells (%) affter 3 days incu
Each expeeriment was peerformed in dup
plicate.
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IIncubation of H929 cells with
w
curcumin
n (30M) or LEN
L
(2.5 mM
M) for 3 dayss resulted in 226.35% (±1.066) and
330.81%(±2.98)) apoptotic cellls respectively
y. When 30 M
M curcumin w
was combined w
with 2.5 mM L
LEN, 50.4% ((±3.37)
aapoptotic cellss were detected by flow cyttometry (see Figure
F
2), and the increase w
was significantt compared to either
ccurcumin alone or lenalidom
mide alone (anov
va p=0.0026).

he percentage of
o apoptotic ceells measured as annexin V positive by flow cytometry is shown for each
Figure 2. Th
culture condition: curcumin
n at 30 M (C30), lenalidomid
de at 2.5 mM (L
Len 2.5) and ccombination off both curcuminn and
lenalidomide (C+Len). Miinimal cell deaath was obserrved with vehiicle control coontaining 1% DMSO. Errorr bar
represents SE
EM of duplicate experimen
nts. The differrence in vehiccle control (V
VC) and untreaated cells wass not
significant (p
p=0.16).

3.2 Effec
ct of curcumin and
d lenalido
omide on
n cereblon gene expression
L
Lenalidomide suppresses exp
pression of thee cereblon gene (CRBN) resuulting in a cytootoxic effect oon myeloma ceells [17].
Change in the level of mRN
C
NA expression of CRBN waas tested in thee curcumin-treeated H929 cellls by RT-PCR
R, with
L
LEN-treated ceells acting as a positive contro
ol. A similar deecrease (4.71 ffold) in CRBN mRNA expresssion was obserrved in
ccurcumin-treatted and LEN-trreated H929 ceells. A combinaation of curcum
min and LEN rresulted in an inncreased supprression
((7.7 fold) of CRBN mRNA expression
e
(seee Figure 3).

Figure 3. A combination of curcumin (C)
and lenalid
domide (LEN
N) reduced the
expression off cereblon and
d MRP compaared
to single agen
nts alone. Curccumin alone haad a
stronger effecct in reducing the expression
n of
MDR than lenalidomide alone or a
combination of both (C+LE
EN). Error bars are
from 3 separaate experimentts each perform
med
in duplicate.
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3.3 Effect of curcumin and lenalidomide on multi-drug resistant genes
The expression of genes associated with multidrug resistance (MDR) in multiple myeloma, MDR1 (p-gp) and the MDR
protein (MRP), were analysed by real time RT-PCR. Treatment of H929 cells with either  of curcumin or 2.5 mM of
lenalidomide for 48 hours decreased the expression of MDR compared to untreated cells. There was a 4-fold reduction of
MDR mRNA expression as a result of curcumin treatment, while in the lenalidomide-treated cells there was a 2-fold
reduction of MDR mRNA expression compared to the untreated controls. A combination of the two agents resulted in a
3-fold reduction in the mRNA expression of the MDR gene (see Figure 3).
MRP mRNA expression decreased by 2 and 1.5-fold respectively after incubating the cells with either curcumin or
lenalidomide as compared to untreated controls. Enhanced reduction of MRP mRNA expression was observed when cells
were treated with a combination of both agents. An approximate 4-fold reduction in the MRP mRNA level was evident
compared to the untreated controls (see Figure 3).

4 Discussion
This study demonstrates that both curcumin and lenalidomide exert a cytotoxic effect on H929 myeloma cells resulting in
apoptosis. Furthermore, the combination of curcumin and lenalidomide enhances apoptosis of these cells. These findings
are similar to those of previous studies with myeloma cell lines (U266 and H929) using curcumin and a less potent
immunomodulatory drug, i.e. thalidomide [10] and bortezomib [11] respectively. The H929 cell line was chosen for this
study because it harbours the t(4; 14) translocation, whereas the U266 cell line carries a t(11; 14) translocation [18]. Patients
that carry the t(11; 14) translocation are considered “low risk”, while those harbouring the t(4; 14) translocation are
associated with a poor prognosis that is only partially improved by the use of lenalidomide [19]. The lack of response in
patients with t(4; 14) probably explains our in vitro observation that the H929 cells were only partially responsive to
lenalidomide which reached a plateau at 3mM.
Recent studies have demonstrated that the cereblon (CRBN) gene is a primary target for IMiD drugs like thalidomide and
lenalidomide [17]. Exposure of myeloma cells to lenalidomide results in cell death, and this cytotoxic effect is accompanied
by suppression of the CRBN gene [17]. Since a combination of curcumin and lenalidomide resulted in an increased
apoptotic effect in this study, we sought to analyse if this cytotoxicity might be related to a change in the gene expression
of CRBN mRNA. Our results confirm that mRNA expression of CRBN is similarly reduced in the presence of either
curcumin or lenalidomide as compared to untreated controls and the reduction is almost doubled when the two agents were
used in combination. These findings indicate that curcumin can enhance the cytotoxic effect of lenalidomide via
suppression of the cereblon gene.
Multidrug resistance is a significant factor that contributes to the success or failure of chemotherapy in various types of
cancer including multiple myeloma. Myeloma patients often show resistance to a number of cytotoxic drugs once they
develop resistance to doxorubicin-based chemotherapy [20]. Here, we also examined the effect of curcumin and
lenalidomide as single agents and in combination on the expression of two common multidrug resistant genes, the MDR1,
encoding the P-glycoprotein, and the MRP gene which encodes the multidrug resistant protein. As single agents, both
curcumin and lenalidomide reduced the expression of both MDR1 and MRP. A combination of both agents resulted in
enhanced reduction of MRP expression. This observation has not been previously reported.
Exposure of H929 cells to curcumin alone resulted in a greater reduction in MDR1 compared to lenalidomide alone or a
combination of both agents. Chen et al [21] report that lenalidomide is not a P-gp inhibitor in vitro or in vivo. This may
explain the greater MDR1 response to curcumin than lenalidomide inH929 cells. Curcumin has also been shown to reduce
MDR1 gene expression in primary cells isolated from newly diagnosed and relapsed leukaemia patients [22].
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About one third of patients with relapsed or refractory myeloma respond to thalidomide-containing treatment, and this
response rate improves to 60% with a lenalidomide-containing regimen [23]. Lenalidomide-containing therapy also has the
added advantage of overcoming resistance to both conventional chemotherapy and to thalidomide [24, 25]. A recent review
by Quach et al [4] refers to the future optimization of lenalidomide’s use in combination with other therapeutic agents.
Curcumin-induced inhibition of NF-kB, which results in decreased transcription of various cytokines, could potentially
augment lenalidomide’s ability to disrupt bone marrow stromal support for multiple myeloma cells. Our findings and
those of Sung et al [10] suggest that curcumin can potentiate not only the cytotoxic effect of lenalidomide or thalidomide,
but also enhance the chemo-sensitising effects of these agents. The clinical implications arising from these observations
are two pronged: i) curcumin studies can be designed to assess the additive effects of curcumin to the current treatment
protocols such as MPR (melphalan-prednisolone-lenalidomide[4]) and Len-Dex (lenalidomide-dexamethasone[4]) and ii)
curcumin may be used as an alternative to corticosteroids in such protocols.
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